At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 17 enrolled
Drug / intervention
6,8-bis(benzylthio)octanoic aciddrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Pilot Open-Label Clinical Trial of CPI-613 in Patients With Advanced Bile Duct Cancers
In Brief
A Phase 2 clinical trial evaluating 6,8-bis(benzylthio)octanoic acid for Adult Primary Cholangiocellular Carcinoma and 8 related conditions. Completed, enrolled 17 participants across 1 site.
Detailed Summary
This pilot clinical trial studies 6,8-bis(benzylthio)octanoic acid in treating patients with advanced or metastatic cholangiocarcinoma that cannot be removed by surgery. 6,8-Bis(benzylthio)octanoic acid may stop the growth of cholangiocarcinoma by blocking blood flow to the tumor
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdult Primary Cholangiocellular Carcinoma, Advanced Adult Primary Liver Cancer, Cholangiocarcinoma of the Extrahepatic Bile Duct, Cholangiocarcinoma of the Gallbladder, Localized Unresectable Adult Primary Liver Cancer, Metastatic Extrahepatic Bile Duct Cancer, Recurrent Adult Primary Liver Cancer, Recurrent Extrahepatic Bile Duct Cancer, Unresectable Extrahepatic Bile Duct Cancer
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJan 2013
Enrollment StartMay 2013
Primary CompletionApr 2018
Study CompletionMay 2018
TodayJul 2026
First PostedJan 11, 2013
Enrollment StartMay 1, 2013
Primary CompletionApr 1, 2018
Study CompletionMay 18, 2018
TodayJul 2, 2026
Enrollment to primary: 4.9 yearsPosted 13.5 years ago
Interventions
6,8-bis(benzylthio)octanoic aciddrug
Given IV